{"product_id":"novartis-bcg-matrix","title":"Novartis Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the strategic power of the Novartis BCG Matrix, a vital tool for understanding product portfolio performance. See which of Novartis's offerings are market leaders (Stars), consistent revenue generators (Cash Cows), potential growth opportunities (Question Marks), or underperforming assets (Dogs).\u003c\/p\u003e\n\u003cp\u003eThis glimpse into the Novartis BCG Matrix is just the beginning. Purchase the full report for a comprehensive quadrant-by-quadrant analysis, data-driven insights, and actionable strategies to optimize your investment and product development decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKisqali (ribociclib)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKisqali, an oncology therapy for breast cancer, is a significant growth driver for Novartis.  Its sales reached $1.177 billion in Q2 2025, marking a substantial 64% increase in constant currencies.\u003c\/p\u003e\n\u003cp\u003eThe drug's recent U.S. approval for early-stage breast cancer and expanded use in metastatic settings are propelling rapid adoption. This strong performance positions Kisqali as a key future blockbuster, with projected peak sales of $8 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeqvio (inclisiran)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLeqvio, a groundbreaking cholesterol-lowering medication, has shown remarkable momentum since its introduction.  In the first quarter of 2025, its sales experienced a substantial 70% increase, reaching $257 million. This impressive growth is fueled by its innovative siRNA technology and expanding patient uptake across various global markets.\u003c\/p\u003e\n\u003cp\u003eThe drug's unique mechanism of action and the growing recognition of its efficacy are key drivers behind this acceleration. Novartis is optimistic about Leqvio's sustained strong performance and its ability to capture a larger market share, solidifying its importance within the company's cardiovascular offerings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePluvicto (lutetium vipivotide tetraxetan)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePluvicto, a targeted radioligand therapy for prostate cancer, is a significant growth driver for Novartis.  Its Q2 2025 sales hit $454 million, marking a substantial 22% jump from the previous quarter, underscoring its strong market momentum.\u003c\/p\u003e\n\u003cp\u003eThe FDA's approval in April 2024 for use before chemotherapy has broadened Pluvicto's accessibility, allowing Novartis to pursue its integration into earlier treatment stages. This strategic move is expected to further fuel its market penetration.\u003c\/p\u003e\n\u003cp\u003eWith projected peak sales exceeding $5 billion, Pluvicto is positioned as a star performer within Novartis' oncology pipeline, reflecting its therapeutic innovation and commercial success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScemblix (asciminib)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScemblix, a groundbreaking treatment for chronic myeloid leukemia (CML), represents a significant asset for Novartis. Its recent FDA accelerated approval for newly diagnosed Philadelphia chromosome-positive CML in chronic phase broadens its market reach considerably.\u003c\/p\u003e\n\u003cp\u003eWith patent protection anticipated to last into the mid-2030s, Novartis has a clear runway for Scemblix's commercial success. The company views this drug as a key driver of differentiated, long-term growth, bolstered by compelling clinical trial data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion:\u003c\/strong\u003e FDA approval for newly diagnosed CML patients in chronic phase enhances Scemblix's addressable market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLong-Term Growth Driver:\u003c\/strong\u003e Patent exclusivity extending to the mid-2030s positions Scemblix for sustained revenue generation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Validation:\u003c\/strong\u003e Positive clinical trial outcomes provide strong evidence supporting the drug's efficacy and future potential.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKesimpta (ofatumumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKesimpta, a Novartis treatment for multiple sclerosis, is a standout performer. Its sales surged by 49% in 2024, reaching $899 million in the first quarter of 2025. This rapid growth positions Kesimpta as a star asset within Novartis' portfolio.\u003c\/p\u003e\n\u003cp\u003eThe drug's success is fueled by its convenient at-home administration and its strong impact within the neuroscience sector. This makes it a crucial revenue generator for Novartis, particularly within its immunology division.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eKesimpta sales growth:\u003c\/strong\u003e 49% in 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQ1 2025 sales:\u003c\/strong\u003e $899 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey drivers:\u003c\/strong\u003e Home-administered convenience and neuroscience performance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBCG Matrix classification:\u003c\/strong\u003e Star asset, rapid growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTop Performers: High-Growth Products Driving Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovartis' \"Stars\" in the BCG Matrix represent products with high market share and high growth potential, demanding significant investment to maintain their leading positions. These are the company's current growth engines, poised for continued success.\u003c\/p\u003e\n\u003cp\u003eKisqali, an oncology therapy, saw its sales reach $1.177 billion in Q2 2025, a 64% constant currency increase, driven by expanded approvals. Leqvio, a cholesterol-lowering medication, achieved $257 million in Q1 2025 sales, up 70%, due to its innovative technology. Pluvicto, a prostate cancer therapy, reported $454 million in Q2 2025 sales, a 22% increase, benefiting from earlier treatment approvals and projected peak sales over $5 billion. Kesimpta, for multiple sclerosis, posted $899 million in Q1 2025 sales, a 49% rise in 2024, attributed to its convenient administration.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eTherapeutic Area\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Sales (USD billions)\u003c\/th\u003e\n\u003cth\u003eYoY Growth (Constant Currency)\u003c\/th\u003e\n\u003cth\u003eProjected Peak Sales (USD billions)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKisqali\u003c\/td\u003e\n\u003ctd\u003eOncology (Breast Cancer)\u003c\/td\u003e\n\u003ctd\u003e1.177\u003c\/td\u003e\n\u003ctd\u003e64%\u003c\/td\u003e\n\u003ctd\u003e8.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeqvio\u003c\/td\u003e\n\u003ctd\u003eCardiovascular (Cholesterol)\u003c\/td\u003e\n\u003ctd\u003e0.257 (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e70% (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePluvicto\u003c\/td\u003e\n\u003ctd\u003eOncology (Prostate Cancer)\u003c\/td\u003e\n\u003ctd\u003e0.454\u003c\/td\u003e\n\u003ctd\u003e22% (QoQ)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;5.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKesimpta\u003c\/td\u003e\n\u003ctd\u003eImmunology (Multiple Sclerosis)\u003c\/td\u003e\n\u003ctd\u003e0.899 (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e49% (2024)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Novartis BCG Matrix analyzes its product portfolio across Stars, Cash Cows, Question Marks, and Dogs to guide strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Novartis BCG Matrix offers a clear visual, simplifying complex portfolio decisions and alleviating the pain of strategic uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntresto (sacubitril\/valsartan)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntresto, a cornerstone treatment for heart failure and hypertension, demonstrated impressive financial performance, achieving $7.8 billion in sales for 2024. This strong market presence positions it as a significant cash generator within Novartis's portfolio.\u003c\/p\u003e\n\u003cp\u003eThe drug's continued robust demand is further evidenced by its $2.357 billion in sales during the second quarter of 2025. While potential U.S. generic competition looms in mid-2025, Novartis is actively working to protect its market exclusivity, particularly focusing on sustained growth in international markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCosentyx (secukinumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCosentyx, a leading immunology treatment for conditions like psoriasis, generated an impressive $6.141 billion in sales for Novartis in 2024. This strong performance continued into the first quarter of 2025, with sales reaching $1.53 billion.\u003c\/p\u003e\n\u003cp\u003eThe drug's expanding approved uses and widespread acceptance by physicians have solidified its significant market position. Cosentyx remains a crucial contributor to Novartis's immunology portfolio, consistently delivering robust and reliable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePromacta\/Revolade (eltrombopag)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePromacta\/Revolade, a key treatment for thrombocytopenia, demonstrated robust performance with $2.216 billion in sales during 2024. This drug has consistently been a significant revenue driver for Novartis, underscoring its importance within the company's portfolio.\u003c\/p\u003e\n\u003cp\u003eDespite the anticipation of potential U.S. generic competition in mid-2025, Novartis is actively pursuing strategies to extend Promacta\/Revolade's market life and maximize its value. This focus reflects the drug's established position and its ongoing contribution to the company's financial health.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTafinlar + Mekinist (dabrafenib + trametinib)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTafinlar + Mekinist, a combination therapy for oncology, demonstrated robust sales of $2.058 billion in 2024. This performance solidifies its position as a significant contributor to Novartis' revenue streams.\u003c\/p\u003e\n\u003cp\u003eThe sustained success of Tafinlar + Mekinist highlights its role as a dependable cash cow within Novartis' diverse oncology offerings. Its established efficacy across multiple cancer types ensures consistent market demand and predictable revenue generation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct:\u003c\/strong\u003e Tafinlar + Mekinist (dabrafenib + trametinib)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024 Sales:\u003c\/strong\u003e $2.058 billion\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTherapeutic Area:\u003c\/strong\u003e Oncology combination therapy\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Position:\u003c\/strong\u003e Consistent performer and reliable revenue generator\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJakavi (ruxolitinib)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJakavi, a significant oncology drug from Novartis, demonstrated robust financial performance in 2024, generating sales of $1.936 billion. This strong revenue underscores its established position within its therapeutic market, making it a cornerstone for consistent cash flow and bolstering Novartis's overall financial stability.\u003c\/p\u003e\n\u003cp\u003eThe drug's sustained sales highlight its function as a reliable income generator for the company, solidifying its status as a cash cow within the BCG matrix framework.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct:\u003c\/strong\u003e Jakavi (ruxolitinib)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024 Sales:\u003c\/strong\u003e $1.936 billion\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTherapeutic Area:\u003c\/strong\u003e Oncology\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBCG Matrix Classification:\u003c\/strong\u003e Cash Cow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash Cows: The Revenue Powerhouses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThese products represent Novartis's established, high-performing assets that generate substantial and consistent revenue with minimal investment. Their strong market share and continued demand solidify their role as dependable cash cows, funding innovation and growth in other areas of the company's portfolio.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Sales (USD billions)\u003c\/th\u003e\n\u003cth\u003eTherapeutic Area\u003c\/th\u003e\n\u003cth\u003eBCG Matrix Classification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntresto\u003c\/td\u003e\n\u003ctd\u003e7.8\u003c\/td\u003e\n\u003ctd\u003eCardiovascular\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCosentyx\u003c\/td\u003e\n\u003ctd\u003e6.141\u003c\/td\u003e\n\u003ctd\u003eImmunology\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePromacta\/Revolade\u003c\/td\u003e\n\u003ctd\u003e2.216\u003c\/td\u003e\n\u003ctd\u003eHematology\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTafinlar + Mekinist\u003c\/td\u003e\n\u003ctd\u003e2.058\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJakavi\u003c\/td\u003e\n\u003ctd\u003e1.936\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eNovartis BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Novartis BCG Matrix preview you're seeing is the identical, fully formatted document you will receive immediately after your purchase. This means no watermarks, no demo content, and no altered data—just the complete, analysis-ready report designed for strategic decision-making.\u003c\/p\u003e\n\u003cp\u003eRest assured, the Novartis BCG Matrix you're previewing is the exact file that will be delivered to you upon completion of your purchase. This professional report is ready for immediate use, allowing you to seamlessly integrate its strategic insights into your business planning and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610917945721,"sku":"novartis-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/novartis-bcg-matrix.png?v=1754748727","url":"https:\/\/growthsharematrix.com\/products\/novartis-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}